RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi  by Helmbold, Peter et al.
RASSF10 Promoter Hypermethylation Is Frequent
in Malignant Melanoma of the Skin but Uncommon
in Nevus Cell Nevi
Peter Helmbold1, Antje M. Richter2, Sara Walesch2, Alexander Skorokhod1, Wolfgang Ch. Marsch3,
Alexander Enk1 and Reinhard H. Dammann2
The Ras association domain family (RASSF) consists of several tumor suppressor genes, which are frequently
silenced in human cancers. We analyzed the epigenetic inactivation of RASSF2 and RASSF10 in malignant
melanoma (MM) of the skin, including 5 MM cell lines, 28 primary MM, 33 metastases of MM, 47 nevus cell nevi
(NCN), and 22 control tissues. The RASSF2 promoter was epigenetically downregulated in two MM cell lines
only, but not in any of the investigated tumor samples. In contrast, hypermethylation of the RASSF10 promoter
was found in all investigated cell lines, 19/28 (68%) of the primary MM and 30/33 (91%) of the MM metastases,
2/18 (11%) of the dysplastic NCN, and 0/29 (0%) of the non-dysplastic NCN (difference between MM and all nevi,
Po0.001). RASSF10 promoter hypermethylation correlated with a reduced RASSF10 mRNA expression in 3/4 MM
cell lines, and treatment with a DNA methylation inhibitor reactivated RASSF10 transcription. Furthermore,
immunohistological RASSF10 expression corresponds negatively to its promoter methylation state. In summary,
RASSF10 proved to be a characteristically epigenetically silenced tumor suppressor in melanomagenesis,
and analysis of RASSF10 methylation status represents a new candidate tool to assist in discrimination between
MM and NCN.
Journal of Investigative Dermatology (2012) 132, 687–694; doi:10.1038/jid.2011.380; published online 24 November 2011
INTRODUCTION
Malignant melanoma (MM) is a malignant tumor of the
skin with a marked rising incidence (Parkin et al., 2005).
Several molecular pathways have been found to be
deregulated in melanocytic tumors, including the Ras-RAF
pathway, the p16INK4a-RB pathway, and the PI3K-AKT path-
way (Miller and Mihm, 2006; Dahl and Guldberg, 2007).
Deregulation of these pathways is accomplished through
activation of proto-oncogenes and inactivation of tumor
suppressor genes. Besides mutation, the epigenetic silencing
of tumor suppressor genes is a frequent event in malig-
nant tumor (Jones and Baylin, 2002; Rothhammer and
Bosserhoff, 2007). In MM, pTEN promoter hypermethyla-
tion but not BRAF mutations have negative survival effects
(Lahtz et al., 2010). This inactivation is achieved by aberrant
methylation of the CpG island promoters in tumors (Jones
and Baylin, 2007). In this context, Ras effectors are of special
interest. The Ras association domain family (RASSF) is a
group of Ras effectors. It consists of 10 different genes
(RASSF1–RASSF10) that are expressed into different isoforms
(van der Weyden and Adams, 2007; Richter et al., 2009).
Several of these genes (RASSF1A, RASSF2A, RASSF5
[NORE1], RASSF6) encode tumor suppressors, which are
involved in proliferation, cell cycle regulation, microtubule
stability, and apoptosis (Khokhlatchev et al., 2002; Vos et al.,
2003; Allen et al., 2007; Richter et al., 2009, 2010;
Schagdarsurengin et al., 2010). Epigenetic inactivation of
RASSF genes occurs at high frequencies in different tumors.
The most prominent member of the family is the RASSF1A
tumor suppressor, which is frequently epigenetically silenced
in different cancers (Dammann et al., 2000). RASSF1A
is inactivated through hypermethylation of its CpG island
promoter in primary MM (Spugnardi et al., 2003; Furuta
et al., 2004; Hoon et al., 2004; Reifenberger et al., 2004;
Rastetter et al., 2007; Tellez et al., 2009). In addition to
RASSF1A, epigenetic silencing of RASSF5 has been reported
in different tumor entities (Tommasi et al., 2002; Hesson
et al., 2003; Schagdarsurengin et al., 2006, 2010; Steinmann
et al., 2009). In MM, methylation of RASSF5 was not
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observed (Tommasi et al., 2002). RASSF10 is a new
member of the N-terminal RASSF family that also includes
RASSF7, RASSF8, and RASSF9 (Falvella et al., 2006;
Sherwood et al., 2008). Hypermethylation of RASSF3,
RASSF4, RASSF7, and RASSF8 occurs rarely in human
cancers, and RASSF6 and RASSF9 contain no CpG island
promoters (Dammann et al., 2005; Richter et al., 2009;
Underhill-Day et al., 2011). Recently, we have reported that
RASSF2 and RASSF10 can be inactivated in some human
cancers (Schagdarsurengin et al., 2009, 2010; Steinmann
et al., 2009). RASSF10 is frequently hypermethylated in
childhood leukemias, thyroid cancer, and glioma (Hesson
et al., 2009; Schagdarsurengin et al., 2009; Hill et al., 2011).
In MM, epigenetic silencing of RASSF2 and RASSF10 has not
been investigated.
The aim of our study was to illuminate the epigenetic
deactivation of RASSF2 and RASSF10 in cutaneous MM.
Here, we report that RASSF10 is—in contrast to benign
melanocytic lesions—frequently hypermethylated in MM.
RESULTS
RNA expression of RASSF2 and RASS10 in melanoma cell lines
First, we analyzed the expression of RASSF2 and RASSF10 in
five MM cell lines by reverse transcription-PCR (Figure 1).
RASSF2 mRNA was reduced in C8161 and MeWo (Figure
1a). Treatment of these two cell lines with 5-aza-20-
deoxycyticine (aza), a substance that inhibits de novo DNA
methylation (Jones and Taylor, 1980), resulted in increased
RASSF2 mRNA levels (Figure 1a and b). Reduced expression
of RASSF10 was found in buf1280, C8161, and MeWo
compared with IGR1 (Figure 1a and c). Treatment
of these cell lines with aza significantly increased the
expression of RASSF10 for buf1280, C8161, and MeWo
(Figure 1a and c). These results indicate that silencing of
RASSF2 and RASSF10 can occur in MM cell lines.
Methylation of RASSF2 promoter was not detected in primary
MM
Subsequently, we analyzed the methylation status of the
RASSF2 promoter region in five MM cell lines (buf1280,
C8161, IGR1, MeWo, and SK-Mel13), 23 primary MM, 28
metastases of MM, and 38 nevus cell nevi (NCN), as well as
3 control tissues by combined bisulfite restriction analysis
(COBRA; Figure 2). Only the MM cell lines C8161 and
MeWo were partially methylated at the RASSF2 promoter
(Figure 2a). All analyzed primary tumors, metastases, NCN,
or control tissues were unmethylated for RASSF2 (Figure 2b
and c and Supplementary Tables S1 and S2 online). Our
data suggest that epigenetic inactivation of RASSF2 occurred
only in two MM cell lines, and this correlates with its
expression data.
RASSF10 promoter hypermethylation occurs frequently in
melanoma, is a rare event in dysplastic nevi, and was not found
in non-dysplastic nevi
All five analyzed cell lines were at least partially methylated
for the RASSF10 promoter (Figure 3a). The methylation status
of RASSF10 for C8161, buf1280, and IGR1 was confirmed by
pyrosequencing (Figure 4). High percentage of CpG methyla-
tion at six CpG was found in C8161 and buf1280, with an
average of 80% and 72% methylation, respectively (Figure 4).
For IGR1, which exhibits weaker methylation in COBRA, an
average of 11% was revealed by pyrosequencing (Figure 4).
The RASSF10 methylation status in MM cell lines matched
with its expression data.
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Figure 1. RNA expression of RASSF2 and RASSF10 in malignant melanoma (MM) cell lines. MM cell lines (buf1280, C8161, IGR1, and MeWo) were
treated for 4 days with the indicated concentrations of 5-aza-deoxycyticine (aza). RNA was isolated and analyzed by reverse transcription PCR (RT-PCR).
(a) Products for RASSF2 (236 bp) and RASSF10 (243 bp) and a 100 bp ladder (M) were resolved on 2% gel. Expression of b-actin (ACTB; 225 bp)
was determined as a control for RNA integrity. (b) Reexpression of RASSF2 was analyzed by quantitative RT-PCR, normalized to ACTB expression, and plotted
relative to the C8161 control (¼ 1). (c) Expression of RASSF10 was normalized to ACTB and plotted relative to C8161 (¼ 1).
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Subsequently, we analyzed the methylation of the
RASSF10 in primary MM, MM metastases, NCN, and controls
by COBRA (Figure 3 and Supplementary Tables S1 and S2
online). In 19 out of 28 (68%) primary MM, the promoter of
RASSF10 was partially methylated and a restriction product
with 192 bp was detected (Figure 3b and Supplementary
Tables S1 and S2 online). Methylation of selected MM
samples was confirmed by pyrosequencing (Figure 4). More-
over, methylation of RASSF10 was found in 10 out of 10
(100%) skin metastases of MM, 5 out of 6 (83%) lymph node
(LN) metastases of MM, and 15 out of 17 (88%) brain
metastases of MM (Figure 3c and Supplementary Tables S1
and S2 online). In contrast, none of the 29 (0%) non-
dysplastic NCN showed methylation of RASSF10. We
analyzed a group of dysplastic (Clark) NCN with intermediate
dignity between completely benign NCN and MM. In all, 2
out of 18 (11%) Clark NCN showed methylation of RASSF10
by COBRA (Figure 3b and Supplementary Tables S1 and S2
online). By pyrosequencing, the background was under 10%
hypermethylated cells in all samples that were negative by
COBRA (Figure 4).
Statistical analysis revealed highly a significant difference
of RASSF10 promoter methylation state between all MM
(primaries and metastases) and NCN (48/60 vs. 2/47 methyla-
ted tumors, Po0.001, Fisher’s exact test, Figure 5). The
subgroup analysis between MM primaries alone and NCN
was significant as well (19/28 vs. 2/47 methylated tumors,
P¼0.014). In the total of 75 primary melanocytic tumors (28
primary MM, 47 NCN), the sensitivity to detect MM by
COBRA of the RASSF10 promoter was 67.9%, and the
specificity of this analysis was 95.7%. Furthermore, we found
a slight but significant difference of RASSF10 promoter state
between MM primaries and metastases (19/28 vs. 30/33
methylated tumors, P¼0.025, two-tailed significance,
Mann–Whitney test). In contrast, there was no significant
difference in RASSF10 promoter state detectable between
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Figure 2. Methylation analysis of RASSF2. Methylation of the RASSF2 promoter in (a) malignant melanoma (MM) cell lines, (b) nevus cell nevi (NCN),
skin metastases of MM (SM), or primary MM (superficial spreading melanoma (SSM)), and (c) brain metastases of MM (BM). The methylation status of the
RASSF2 promoter was analyzed by combined bisulfite restriction analysis. PCR products (100 bp or 224 bp) from bisulfite-treated DNA were digested
(TaqI, T) and mock digested () and resolved on 2% gel. In vitro-methylated DNA (Methy) was used as positive control. Sizes of a 100 bp ladder (M) are marked.
Methy, methylation control; m, methylated; pm, partially methylated; u, unmethylated; numbers in brackets, case numbers of Supplementary Tables S1
and S2 online.
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Figure 3. Methylation analysis of RASSF10. Methylation of the RASSF10 promoter in (a) malignant melanoma (MM) cell lines, (b) nevus cell nevi (NCN)
or primary MM (superficial spreading melanoma (SSM), nodular melanoma (NM)), and (c) MM metastasis. PCR products (241 bp) were digested (TaqI, T)
and mock digested () and resolved on 2% gel. The arrowheads indicate a digest product at 192 bp. Sizes of a 100 bp ladder (M) are marked (Methy,
methylation control; m, methylated; pm, partially methylated; u, unmethylated; numbers in brackets, case numbers of Supplementary Tables S1 and S2 online).
BM, brain metastasis; LNM, lymph node metastasis; SM, skin metastasis.
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in situ and invasive MM primaries (4/6 vs. 15/22), or different
types of metastases (skin and LN metastases versus brain
metastases, 15/16 vs. 15/17, respectively). In summary, our
data suggest that epigenetic silencing of RASSF10 is a
frequently found in cutaneous MM and MM metastases,
rarely found in dysplastic NCN, and was not detectable in
non-dyplastic NCN.
Immunohistological investigations on RASSF10 expression
The used noncommercial anti-RASSF10 antibody was not
suitable for working on paraffin-embedded material (data not
shown). Thus, we analyzed cryosections of five MM
metastases (all with hypermethylated RASSF10 promoter,
COBRA) and five NCN (all with unmethylated RASSF10
promoter; Figure 6). Although RASSF10 expression was
strong in two out of five NCN and weak in three out of five
NCN, focal strong RASSF10 expression was detectable in one
MM, weak diffuse expression in one MM, and no expression
was detectable in three out of five MM (Figure 6g–k). We
conclude that RASSF10 expression corresponds negatively to
its promoter methylation state, but there is no strong
correlation between promoter methylation and negative gene
expression.
RASSF10 promoter hypermethylation and clinical data
In the group of patients who suffered from primary MM with
hypermethylated RASSF10 promoter, 9/28 died during the
follow-up. In contrast, there was no death reported in the
unmethylated MM group (nine patients). This tendency
proved no significance in univariate Cox regression owing
to the asymmetry of the two groups together with a relative
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Figure 4. Methylation analysis of the RASSF10 promoter by pyrosequencing. PCR products obtained from bisulfite PCR of malignant melanoma (MM) cell
lines (C8161, buf1280, and IGR1), non-Hodgkin lymphoma (NHL, diffuse large B-cell lymphoma of the skin), nodular MM (NM), and dyplastic (Clark) nevus
cell nevi (NCN) were analyzed by pyrosequencing. The frequency of CpG methylation is indicated (arrowheads, bisulfite controls; numbers in brackets,
case numbers of Supplementary Tables S1 and S2 online).
Nevus cell neviMelanomas
50
40
30
20
10
0
Hypermethylated
Unmethylated
RASSF10 promoter
P < 0.001
N
um
be
r o
f c
as
es
Figure 5. Comparison between malignant melanoma (primaries, metastases)
and nevus cell nevi (including dysplastic Clark nevi). Bar chart indicates
the number of tumors with unmethylated or hypermethylated RASSF10
promoter regions. Fisher’s exact test.
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small sample size and a relatively short follow-up time.
Further details of survival and recurrence states of the patients
are given in Supplementary Tables S1 and S2 online.
Furthermore, we found no correlation of sex, age, tumor
thickness or ulceration of the primaries, mitotic index
(number of mitoses in 10 microscopic high-power fields),
inflammation (no/few versus medium/high inflammatory
infiltration), predominating tumor cell type (epitheloid versus
other), or the percentage of tumor tissue with RASSF10
promoter state (age and tumor thickness, Spearman correla-
tion, other factors, Fisher’s exact test). The distribution of age
was asymmetric with nonsignificant higher ages in the
RASSF10 hypermethylated melanocytic samples (Supplemen-
tary Figure S2 online). Thus, we studied the predictive power
of age and that of the dignity diagnosis together in a logistic
regression model (Supplementary Table S4 online). We found
no predictive influence of age but a high impact of the
diagnosis (NCN versus MM) on RASSF10 promoter methyla-
tion state.
DISCUSSION
The RASSF family consists of 10 members, which encode a
Ras association domain. RASSF10 was recently identified as a
member that harbors a N-terminal Ras association domain
and lacks the Sav-Ras-Hippo interaction domain that is found
in the classical RASSF members 1–6 (Sherwood et al., 2008;
Richter et al., 2009; Underhill-Day et al., 2011). Here we
report that RASSF10 is frequently hypermethylated in cuta-
neous MM, but not in NCN. To the best of our knowledge, this
is the first study that reports intensive hypermethylation of the
RASSF10 promoter in MM and its metastases. Previously, it
has been reported that RASSF10 is epigenetically inactivated
in thyroid, childhood acute lymphocytic leukemias (ALL), and
glioma (Hesson et al., 2009; Schagdarsurengin et al., 2009;
Hill et al., 2011). We have previously shown that primary
thyroid cancers of patients with cancerous LNs were
significantly hypermethylated for RASSF10 compared with
those with non-affected LNs (Schagdarsurengin et al., 2009).
In childhood ALL, RASSF10 was methylated in 16% of B-ALL
and 88% of T-ALL (Hesson et al., 2009). Recently, its has been
reported that RASSF10 was frequently methylated in grade
II–III astrocytomas and grade IV primary glioblastomas (68%),
but was unmethylated in grade I astrocytomas and in age-
matched control brains (Hill et al., 2011). In secondary
glioblastomas, RASSF10 methylation was an independent
prognostic factor associated with worst progression-free
survival and overall survival, and occurred at an early stage
in their development (Hill et al., 2011).
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Figure 6. Microphotographs of selected samples (case numbers of Supplementary Tables S1 and S2 online); RASSF10 promoter state: M, hypermethylated;
U, unmethylated (&). (a) Compound nevus (case 79). (b) Dysplastic (Clark) nevus (case 96). (c) Superficial spreading melanoma (case 18). (d–f) Clark nevus
with initial transition into malignant melanoma (MM; case 7). (f) Focal intraepidermal transmigration of melanocytes (melan A immunostaining). (g–k) Anti-
RASSF10 antibody (red). (g) Compound nevus with unmethylated RASSF10 promoter, RASSF10 expression in nevus tissue (*), epidermis (arrow), and connective
tissue cells. (h) Isotype control. (i) Skin metastasis of MM with hypermethylated RASSF10 promoter without expression of RASSF10 gene product (*),
epidermis (arrow), and connective tissue cells are RASSF10 positive. (k) Isotype control. Bar¼ 50 mm (a–c, g–k); 100 mm (d); 25mm (e, f).
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Here we reveal that hypermethylation of RASSF10 occurs
frequently in MM, and treatment of three MM cell lines with
an inhibitor of DNA methyltransferases (aza) reactivated its
expression. In IGR1 and SK-MEL13 cells, which exhibit low
methylation rate at the RASSF10 promoter, aza treatment
resulted in a reduced RASSF10 expression (data not shown).
This reduced transcription rate could be attributed to the
cytotoxic effect of aza on melanoma cells (Cortvrindt et al.,
1987). For the cell lines (buf1280, MeWo and C8161) with
high percentage of methylation, a significant reexpression of
RASSF10 occurred. This indicates that RASSF10 methylation
causes its epigenetic silencing in MM. Immunohistologically,
RASSF10 expression corresponds to the RASSF10 promoter
state, but we have not found strong correlation between
promoter methylation and negative gene expression, poten-
tially because of partial methylation in the investigated
MM or regulation of the RASSF10 expression by other factors.
Thus, it would be important to analyze the expression
of RASSF10 in normal melanocytes. In our series of immuno-
histological experiments, intraepidermal melanocytes seemed
to be positive with respect to RASSF10 expression (Figure 6).
We were not able to overcome the problem of separation of
intraepidermal melanocytes from the surrounding RASSF10þ
epidermal keratinocytes by the available antibody (Supple-
mentary Figure S1 online and data not shown). We used a
noncommercial RASSF10 antibody that proved in our hands
as unsuitable to analyze paraffin-embedded material. The
necessity to use cryosections and the lack of a strong correla-
tion between promoter methylation state and the immunohis-
tological results imply that the antibody alone is not a
sufficient tool for analysis of great series of samples.
We have also analyzed the epigenetic inactivation of
RASSF2, a member of the classic RASSFs, which encode a C-
terminal Ras association domain and Sav-Ras-Hippo domain.
Several classic RASSF members are frequently epigenetically
silenced in cancer (e.g., RASSF1A, RASSF2, RASSF5) and
encode prominent tumor suppressors (van der Weyden and
Adams, 2007; Richter et al., 2009). Here, we report that the
epigenetic inactivation of RASSF2 occurs only in MM cell
lines, but was not found in primary tumors. This indicates that
hypermethylation of RASSF2 occurs late in melanomagenesis
or may arise when cancer cell lines are propagated. It has
been shown that methylation of CpG sites is induced by cell
culturing (Antequera et al., 1990; Allegrucci et al., 2007).
The biological functions of the N-terminal RASSFs are
largely unknown, and the role of these RASSFs in tumori-
genesis is still under investigation. Interestingly, RASSF7,
RASSF8, and RASSF10 map near various RAS isoforms
(Sherwood et al., 2008). In cell culture experiments, over-
expression of RASSF10 mediated a reduction in the colony-
forming ability of glioma cell lines (Hill et al., 2011). Thus, it
will be interesting to conduct functional studies in MM
cell lines. Our own unpublished data in prostate cancer
show that RASSF10 overexpression inhibits cell growth and
induces apoptosis of a prostate cancer cell line. Hill et al.
(2011) have generated and characterized a RASSF10-specific
antibody and demonstrated that RASSF10 subcellular locali-
zation is cell cycle dependent, with RASSF10 colocalizing
to centrosomes and associated microtubules during mitosis.
Although CpG island promoters have been predicted for
RASSF7 and RASSF8 (van der Weyden and Adams, 2007;
Richter et al., 2009), it has not been reported yet whether
promoter hypermethylation of RASSF7 and RASSF8 occurs
in MM.
In summary, our results show that hypermethylation
of RASSF10 promoter occurs frequently in MM, but was
not found in NCN. These data suggest that RASSF10
may encode a new melanoma-specific tumor suppressor
gene. Further studies are necessary to elaborate the tumor
suppressor function of RASSF10 in melanomagenesis.
Furthermore, RASSF10 promoter methylation analysis is a
candidate biomarker for an easy applicable tool to differ-
entiate between benign and malignant melanocytic tumors in
routine histology.
MATERIALS AND METHODS
Tissues and cell lines
We analyzed 140 samples of 118 tumors, 6 normal skin tissues, and
6 normal LNs of 119 patients (age 54.3±20.4 years/mean±SD; ratio
male/female¼ 1.7), as well as 5 MM cell lines (Supplementary
Tables S1 and S2 online). The material included 31 samples of
28 primary MM (Tis/T1/T2/T3/T4/unclassified (Balch et al., 2009)
n¼ 6/10/1/4/6/1) of 28 patients (age 67.7±15.4 years/mean±SD),
38 samples of 33 MM metastases (10 skin metastases, 6 LN
metastases, 17 brain metastases; age 66.2±15.7 years/mean±SD
(n¼ 15, age data of patients with brain metastases not available)),
47 samples of 47 NCN (2 junctional NCN, 14 dermal NCN, 13
compound NCN, 18 dysplastic Clark NCN; age 40.2±17.1 years/
mean±SD), and 24 samples of control tissues (6 normal skin
samples, 6 normal LNs, 7 basal cell carcinomas, 1 spiradenoma, 1
keratoakanthoma, as well as 1 diffuse large cell B-cell lymphoma of
the skin; age 63.9±15.8 years/mean±SD). Diagnoses were
established and controlled in each single tumoral or normal control
sample according to histopathological standards by two experienced
dermatopathologists (authors P.H. and W.C.M.; Figure 6). The
proportion of tumor tissue was 55.4±30.8%, mean±SD (range
5–95%). The study was conducted according to the Declaration of
Helsinki Principles. All patients signed informed consent at initial
clinical investigation. The study was approved by local ethics
committees.
Five human MM cell lines—buf1280, C8161, IGR1, MeWo, and
SK-Mel13—were obtained from the Medical Faculty of the Univer-
sity of Halle (generous gift from Dr B Seliger and Dr J Wohlrab) and
cultured in the recommended medium (Seliger et al., 2001;
Klapperstuck et al., 2009). Genomic DNA was extracted from
frozen tissues and cultured cells by a standard proteinase K and
phenol/chloroform procedure (Dammann et al., 2003).
RNA expression analysis of RASSF2 and RASSF10
MM cancer cell lines were treated for 4 days with 5mM of aza (Sigma,
Taufkirchen, Germany). RNA was isolated using TRIzol-Reagent
(Invitrogen, Karlsruhe, Germany; Dammann et al., 2003). To elimi-
nate DNA contamination, 1mg RNA was incubated with 1U DNase I
(Fermentas GmbH, St Leon-Rot, Germany), 1 ml 10 DNase I buffer,
and 10ml DEPC-treated water. After 15minutes of incubation at
room temperature, DNase was inactivated by incubating at 65 1C for
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15minutes. The residue of the mixture was directly reverse trans-
cribed using poly-dT primers and random hexamers in 20 ml of
reverse transcriptase-mix (Promega, Heidelberg, Germany) for
1 hour at 42 1C. Subsequently, 2ml of complementary DNA was
amplified for 34, 45, and 25 cycles with primers for RASSF2,
RASSF10, and b-actin (ACTB), respectively, or analyzed by real-time
PCR (Rotor-Gene 2000, Corbett Life Science, Sydney, Australia) with
Syber Green. Results were normalized to ACTB. PCR pro-
ducts were separated on 2% Tris-borate EDTA agarose gels. Primer
pairs for RASSF2, RASSF10, and ACTB are listed in Supplementary
Table S3 online.
Methylation analysis
Methylation of the RASSF10 or RASSF2 promoter regions was
determined by combined bisulfite restriction analysis (COBRA) and
bisulfite pyrosequencing (Xiong and Laird, 1997). Briefly, 100 ng of
bisulfite-treated DNA was amplified with 10 pmol of primers in a
reaction buffer containing 0.2mM dNTP mix, 1.5mM MgCl2, 10 pmol
of each primer, and 1.5U Taq polymerase (InViTek GmBH, Berlin,
Germany) for 45 cycles. Primer pairs for RASSF10 and RASSF2 are
listed in Supplementary Table S3 online. A measure of 20–50 ng of
PCR products were digested with 10U of TaqI (Fermentas GmBH)
and analyzed on a 2% Tris-borate EDTA agarose gel. Pyrosequen-
cing was used for quantitative methylation analysis of six CpGs at the
RASSF10 promoter. Therefore, DNA was amplified with a biotiny-
lated reverse primer and sequenced with an internal primer
(Supplementary Table S3 online). Pyrosequencing was performed
in PyroMark Q24 according to the PyroMark Gold Q24 Reagents
Handbook (Qiagen, Hilden, Germany). Methylation percentage for
each CpG site was determined.
Immunostaining
Paraffin sections (2 mm) were deparaffinized in graded ethanol, the
endogenous peroxidase was blocked (0.3% H2O2 in methanol), and
heat-induced epitope retrieval was performed by microwaving.
Monoclonal mouse anti-human MART-1/Melan-A, Clone A103
(Dako, Glostrup, Denmark) was applied at a concentration of 1:50
(30minutes, room temperature). Cryosections (3mm) of shock-frozen
tissue material were incubated with polyclonal rabbit anti-RASSF10
(raised against RASSF10 peptide sequence, kindly gifted by Dr F
Latif, Medical and Molecular Genetics, School of Clinical and
Experimental Medicine, College of Medical and Dental Sciences,
Institute of Biomedical Research, University of Birmingham,
Birmingham, West Midlands B15 2TT, UK; Hill et al., 2011) at a
concentration of 1:500 (30minutes, room temperature). Further steps
were performed with the Elite-ABC-Kit (Vector, Burlingame, CA) and
the AEC Substrate System (Dako). Finally, all sections were routinely
counterstained with hemalaun. In RASSF10 staining, 0.5 mgml1
primary rabbit antibody isotype control (Zymed, South San
Francisco, CA) was used for negative control.
Statistical evaluation
Statistical analysis was carried out using SPSS17 (SPSS, Mu¨nchen,
Germany). Categorical variables were plotted into contingency
tables and evaluated using Fisher’s exact test. Linear logistic regres-
sion analysis was performed to study the influence of the patient’s
age on the RASSF10methylation state. All reported P-values are two-
sided and considered significant for Po0.05.
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